FDA Advisory Panel Expectations for PMA Applicants

An FDA advisory panel meeting is one of the most consequential events in a PMA applicant's regulatory journey. It is the point at which the clinical evidence for a novel, high-risk device is scrutinized not only by FDA staff but by a room of independent experts who may probe every assumption, question every statistical choice, and challenge every characterization of the benefit-risk profile. Understanding what panels evaluate, how they are composed, and what preparation is required gives applicants the best possible foundation for a productive panel meeting.

When FDA Convenes an Advisory Panel

FDA is not required to convene an advisory panel for every PMA. Many PMAs are reviewed and approved without a panel meeting. FDA decides to convene a panel when internal review staff determine that outside expert input would meaningfully inform their assessment. The most common scenarios:

• Novel device types: First-in-class devices with no prior U.S. marketing history and no established clinical evidence base often benefit from panel review, where external clinical experts can assess whether the evidence framework is appropriate for the technology.
• Complex or contested benefit-risk assessments: Devices where the clinical benefit is meaningful but accompanied by serious or potentially irreversible risks — or where the patient population is particularly vulnerable — frequently receive panel review to incorporate broader clinical and patient perspectives.
• Policy-driven panel requirements: Certain device categories have been subject to FDA policy commitments to seek panel input. If your device falls into one of these categories, a panel meeting may be a default expectation even if the review itself is not unusually complex.
• Significant public health interest: Devices with large intended patient populations or devices that address conditions with limited treatment alternatives may receive panel review to bring public deliberation into the approval process.

Panel Composition and Structure

FDA's medical device advisory panels are standing committees organized by clinical or device specialty — the Cardiovascular Devices Panel, the Neurological Devices Panel, the Orthopaedic and Rehabilitation Devices Panel, and others. The FDA Committee Management Staff assembles the specific panel roster for a given meeting from the pool of voting members appointed to that standing committee, subject to conflict-of-interest screening.

A typical advisory panel for a device PMA review includes:

• Voting members: Typically 7–12 independent experts — clinicians, surgeons, scientists, and a biostatistician — with specific expertise in the device type or the clinical indication. Voting members are appointed from academic medical centers, clinical practices, and research institutions.
• Patient representative: A voting or non-voting member who represents the experience of patients living with the condition the device addresses. Patient representatives are expected to evaluate benefit-risk from the patient perspective, not just the clinical evidence perspective.
• Consumer representative: A non-voting member representing the general public interest, typically not a clinician or patient with personal experience with the condition.
• FDA staff: CDRH reviewers present FDA's analysis of the PMA, including the clinical evidence summary, benefit-risk assessment, and any concerns or open questions identified during FDA's review. FDA staff ask questions of the applicant and panel members but do not vote.
• Industry representative: In some panel meetings, a non-voting industry representative representing the device manufacturing sector may be included.

What the Panel Evaluates

Advisory panels are asked to evaluate the clinical evidence submitted in the PMA against the specific questions FDA poses for the meeting. Standard evaluation areas include:

• Benefit assessment: Is the primary effectiveness endpoint clinically meaningful? Does the trial evidence demonstrate that the device produces a clinically significant benefit for the intended patient population? Is the benefit durable?
• Risk assessment: What is the nature, severity, frequency, and reversibility of adverse events identified in the clinical data? Were the adverse events adequately captured and reported? Are there patient populations at elevated risk?
• Benefit-risk balance: Do the benefits outweigh the risks for the proposed indication and the proposed patient population? Would the benefit-risk assessment differ materially for specific subpopulations?
• Study design adequacy: Was the clinical study designed to generate reliable evidence? Were the endpoint definitions, comparator selection, follow-up duration, and sample size appropriate?
• Proposed labeling and training: Does the proposed labeling accurately represent the device's benefits and risks? Are training or credentialing requirements appropriate?
• Post-approval conditions: Are post-approval studies or registry requirements appropriate given the current evidence base?

The Panel Vote

After FDA's presentation, the applicant's oral presentation, and a question-and-answer session open to the public, the panel members vote on the specific questions FDA has posed for the meeting. Each voting member casts an individual vote (yes, no, or abstain) and provides a rationale. The votes are tallied and the results are announced at the meeting.

The panel vote is advisory — it is not binding on FDA. FDA may approve a PMA over a panel vote recommending against approval, or may decline to approve a PMA even after a panel vote in favor, if FDA's own assessment of the evidence leads to a different benefit-risk conclusion. In practice, FDA follows the panel's recommendation in the majority of cases, making a panel vote highly influential even if not technically determinative.

Preparing for a Panel Meeting

Panel preparation should begin as soon as FDA notifies the applicant that a panel meeting is scheduled — typically several months before the panel date. Key preparation elements:

• Conduct a detailed review of the panel roster and each panelist's published work to anticipate discipline-specific concerns
• Prepare a formal applicant oral presentation (typically 30–45 minutes) that presents the clinical evidence, benefit-risk analysis, and labeling proposal in a format accessible to a mixed expert audience
• Conduct multiple mock panel sessions with independent experts who will challenge the data with the same rigor a real panel will apply — and prepare the team to respond to difficult questions clearly and concisely under time pressure
• Review all public submissions made to the panel docket — clinicians, patient advocates, and other stakeholders may file public comments that signal specific concerns the panel is likely to raise
• Confirm that the proposed labeling and any post-approval study commitments are consistent with what was submitted in the PMA and with any prior FDA feedback from the review

Frequently Asked Questions

When does FDA convene an advisory panel for a PMA?

FDA convenes an advisory panel when CDRH staff determine that expert outside input would meaningfully inform their review. This occurs most often for: (1) novel Class III device technologies with no prior marketing history in the U.S.; (2) PMAs where the benefit-risk assessment is genuinely complex or contested; (3) device types for which FDA has previously committed to panel review as a matter of policy; or (4) devices that raise significant public health questions warranting public deliberation. FDA is not required to convene a panel for every PMA, and many PMAs are reviewed and approved without a panel meeting. The decision to convene a panel is made during the PMA review — applicants are typically notified several months before the scheduled panel date.

Who sits on an FDA advisory panel?

FDA medical device advisory panels typically include: (1) voting members — clinicians, scientists, and biostatisticians with expertise in the relevant device type or clinical specialty, appointed from academia, clinical practice, and research institutions; (2) a patient representative — a non-voting or voting member who represents the perspective of patients with the condition the device addresses; (3) a consumer representative — a non-voting member who represents the general public's interest; and (4) FDA staff — regulators who present FDA's analysis and ask questions but do not vote. Panel members are screened for conflicts of interest and may be granted waivers for specific, disclosed conflicts when their expertise is deemed essential.

What does an FDA advisory panel vote on?

FDA advisory panels typically vote on one or more questions posed by FDA that are specific to the PMA under review. Common vote questions include: 'Has the applicant provided reasonable assurance of the device's safety?' 'Has the applicant provided reasonable assurance of the device's effectiveness?' 'Do the benefits of the device outweigh its risks for the proposed indication?' Panel members vote yes, no, or abstain on each question and provide an individual rationale for their vote. The panel vote is advisory only — FDA is not required to follow the panel's recommendation, though the agency does so in the majority of cases. A panel vote in favor of approval is a positive signal, but it does not constitute FDA approval.

How should a PMA applicant prepare for an FDA advisory panel?

PMA applicants should begin panel preparation well before the scheduled meeting date — ideally as soon as a panel is announced. Key preparation steps include: (1) reviewing the panel roster and researching panelists' published research, clinical perspectives, and prior panel statements to anticipate the specific concerns each expert is likely to raise; (2) preparing a formal oral presentation (typically 30–45 minutes) that presents the clinical evidence, benefit-risk analysis, and proposed labeling in a format accessible to a mixed expert audience; (3) conducting mock panel sessions with independent experts who can challenge the data and prepare the team to respond under pressure; (4) preparing written responses to the most likely difficult questions — and reviewing the public meeting docket for any public submissions that may signal concerns from clinicians or patient advocates; and (5) ensuring that the labeling proposed reflects any commitments made in the PMA regarding risk mitigation, post-approval studies, or training requirements.